true
Products

Built-in scrub. 

Built-in protection.

BD PosiFlush™ SafeScrub Prefilled Saline Syringe

Contact Us
Background Image
BD PosiFlush™ SafeScrub Prefilled Saline Syringe

Ready to learn more? Let’s have a conversation.

Loading
Overview

The first and only all-in-one scrub and flush solution

With an active disinfection unit built into the tip of the syringe, the all-in-one BD PosiFlush™ SafeScrub Prefilled Saline Flush Syringe is demonstrated to significantly reduce microbial growth associated with potentially serious CRBSIs.*

Giving you one more tool to protect your patients and one less thing to worry about.

*In vitro test results may not be predictive of clinical performance. Demonstrated reduction of the most common causative agents of CRBSI including Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Candida glabrata and Candida albicans.

Benefits

Demonstrated to reduce microbial growth

Built-in active disinfection unit has been proven via in vitro testing to reduce on average ≥99.99% microbial load of the leading microbes associated with CRBSIs*

Designed to reduce touch contamination

All-in-one solution is designed to promote aseptic non-touch technique (ANTTⓇ)


Reinforces adherence to evidence-based best practice

Integrated scrubbing device on the tip of the syringe means this important step simply can’t be missed

Improves efficiency

Seamless integration of scrubbing into workflow means no more searching for alcohol wipes

*In vitro test results may not be predictive of clinical performance. Demonstrated reduction of the most common causative agents of CRBSI including Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Candida glabrata and Candida albicans.

All-in-one scrub and flush

Product details

    Testimonial

    quote-icon
    We’re seeing an increase in preventable catheter-related infections

    Health care facilities are continuing to feel the burden from the pandemic with high rates of nursing turnover and shortages...At the same time, we’re seeing an increase in preventable catheter-related infections, which can be both dangerous to patients and costly for hospitals. It’s not easy to be a frontline caregiver right now. Nurses need efficient and effective solutions to help them advance IV catheter care while improving the safety of their patients.

    —

    Dr. Nathan Gilmore, Chief of Service Critical Care at Hoag Hospital

    Combined
    clinically-proven technologies

    The clinically-proven technology of the BD PosiFlush™ Prefilled Syringes and BD Site-ScrubⓇ IPA Device combined to create an innovative, all-in-one scrub and flush solution—the BD PosiFlush™ SafeScrub Prefilled Saline Flush Syringe.  

    Vascular access devices and CRBSIs

    The first and only all-in-one scrub and flush solution

    Vascular access devices are an integral part of care for many patients—yet the improper care and maintenance of these devices is one of the leading sources of catheter-related bloodstream infections (CRBSIs).1

    Risks of inadequate IV catheter disinfection

    While hub colonization is the strongest predictor of CRBSI, compliance to 'scrub the hub' disinfection guidelines is reported to be as low as 10%1

    Many high-touch surfaces hospital surfaces harbored microbes and increased the risk of infection, contaminating as many as 45% of needle-free connectors1,2

    While the guidelines are clear on the importance of scrubbing the hub before every access, inadequate IV catheter disinfection has been directly linked to CRBSIs1


    Hospitals are under tremendous pressure due to record nursing turnover and shortages, with 35.8% of hospitals in the United States reporting a nurse vacancy of greater than 10%3,4

    Due to the influx of new nurses, there is a decline in the experience of the nursing workforce4



    Burdens of CLABSI

    Patients and healthcare systems are
    feeling the burden

    Card Image

    CLABSI rates increased by 
53% year-over-year during 
the COVID-19 pandemic5

    Card Image

    CLABSI has a 25%
 mortality rate6

     

    Card Image

    On average, it costs $46,000 
to treat one CLABSI patient7

    Products & Accessories
    RELATED PRODUCTS NOT AVAILABLE
    Resources
    Case Studies
    BD promotes clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.
    Learn more
    Literature
    BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
    Learn more
    Training

    BD offers training resources to help improve your clinical practices as part of our goal of advancing the world of health.

    Learn more
    Events

    BD supports the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part in events that excel in advancing the world of health™.

    Learn more

    Ready to experience all-in-one IV catheter care? 
Learn more today.

    BD PosiFlush™ SafeScrub Prefilled Saline Flush Syringe
    Ready to learn more? Let’s have a conversation.

    References

    1. BD Inc. Data on file. In vitro test results may not be predictive of clinical performance. Demonstrated reduction of the most common causative agents of CRBSI including Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Candida glabrata and Candida albicans.

      *In vitro test results may not be predictive of clinical performance. Demonstrated reduction of the most common causative agents of CRBSI including Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Candida glabrata and Candida albicans.

      ⌃As compared to previous BD PosiFlush™ designs.

      BD-89869 (05/23)
    Icon to close the modal

    本网站信息仅供医学专业人士参考，如果您是医学专业人士，请点击确认后进入。如果不是，请关闭本页面。

    true